Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.
2.

Bone quality, and the combination and penetration of cement-bone interface: A comparative micro-CT study of osteoarthritis and rheumatoid arthritis.

Song Y, Zhu F, Lin F, Zhang F, Zhang S.

Medicine (Baltimore). 2018 Aug;97(35):e11987. doi: 10.1097/MD.0000000000011987. Review.

3.

Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.

Lomonte ABV, Radominski SC, Marcolino FMD, Brenol CV, Zerbini CAF, García EG, Akylbekova EL, Rojo R, de Leon DP.

Medicine (Baltimore). 2018 Aug;97(31):e11609. doi: 10.1097/MD.0000000000011609.

4.

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.

Genovese MC, van Adelsberg J, Fan C, Graham NMH, van Hoogstraten H, Parrino J, Mangan EK, Spindler A, Huizinga TWJ, van der Heijde D; EXTEND study investigators.

Rheumatology (Oxford). 2018 Aug 1;57(8):1423-1431. doi: 10.1093/rheumatology/key121.

5.

The effects of reflexology on pain and sleep deprivation in patients with rheumatoid arthritis: A randomized controlled trial.

Bakir E, Baglama SS, Gursoy S.

Complement Ther Clin Pract. 2018 May;31:315-319. doi: 10.1016/j.ctcp.2018.02.017. Epub 2018 Mar 1.

PMID:
29705475
6.

The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial.

Solomon DH, Libby P, Yeomans ND, Wang Q, Wolski KE, Nissen SE, Husni ME.

Rheumatology (Oxford). 2018 Aug 1;57(8):1364-1369. doi: 10.1093/rheumatology/key105.

PMID:
29688503
7.

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.

Genovese MC, Kremer JM, Kartman CE, Schlichting DE, Xie L, Carmack T, Pantojas C, Sanchez Burson J, Tony HP, Macias WL, Rooney TP, Smolen JS.

Rheumatology (Oxford). 2018 May 1;57(5):900-908. doi: 10.1093/rheumatology/kex489.

8.

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Pethö-Schramm A.

Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Erratum in: Rheumatology (Oxford). 2018 Jun 1;57(6):1129.

9.

Biomarkers in connective tissue diseases.

Jog NR, James JA.

J Allergy Clin Immunol. 2017 Dec;140(6):1473-1483. doi: 10.1016/j.jaci.2017.10.003. Review.

PMID:
29221579
10.

Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.

Edwards CJ, Östör AJK, Naisbett-Groet B, Kiely P.

Rheumatology (Oxford). 2018 Jan 1;57(1):84-91. doi: 10.1093/rheumatology/kex358.

PMID:
29155973
11.

Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries.

Kilcher G, Hummel N, Didden EM, Egger M, Reichenbach S; GetReal Work Package 4.

Rheumatology (Oxford). 2018 Feb 1;57(2):354-369. doi: 10.1093/rheumatology/kex394. Review.

PMID:
29149289
12.

Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2018 Feb 1;57(2):309-317. doi: 10.1093/rheumatology/kex386.

PMID:
29095992
13.

Nursing sensitive outcomes in patients with rheumatoid arthritis: A systematic literature review.

Minnock P, McKee G, Kelly A, Carter SC, Menzies V, O'Sullivan D, Richards P, Ndosi M, van Eijk Hustings Y.

Int J Nurs Stud. 2018 Jan;77:115-129. doi: 10.1016/j.ijnurstu.2017.09.005. Epub 2017 Sep 12. Review.

PMID:
29080437
14.
15.

Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.

Guo X, Higgs BW, Bay-Jensen AC, Wu Y, Karsdal MA, Kuziora M, Godwood A, Close D, Ryan PC, Roskos LK, White WI.

Rheumatology (Oxford). 2018 Jan 1;57(1):175-184. doi: 10.1093/rheumatology/kex383.

PMID:
29069507
16.

Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, Hendriks L, Denissen NHAM, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2017 Dec 1;56(12):2179-2189. doi: 10.1093/rheumatology/kex319.

PMID:
29029185
17.

Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?

Ibrahim F, Lorente-Cánovas B, Doré CJ, Bosworth A, Ma MH, Galloway JB, Cope AP, Pande I, Walker D, Scott DL.

Rheumatology (Oxford). 2017 Nov 1;56(11):2004-2014. doi: 10.1093/rheumatology/kex315.

18.

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.

Emery P, Vencovský J, Sylwestrzak A, Leszczynski P, Porawska W, Baranauskaite A, Tseluyko V, Zhdan VM, Stasiuk B, Milasiene R, Barrera Rodriguez AA, Cheong SY, Ghil J.

Rheumatology (Oxford). 2017 Dec 1;56(12):2093-2101. doi: 10.1093/rheumatology/kex269.

19.

The use of glucocorticoids in early rheumatoid arthritis.

Verschueren P, Westhovens R.

Rheumatology (Oxford). 2018 Aug 1;57(8):1316-1317. doi: 10.1093/rheumatology/kex271. Review. No abstract available.

PMID:
28968687
20.

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.

Smolen JS, Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, Yatsyshyn R, Mekic M, Porawska W, Ciferska H, Jedrychowicz-Rosiak K, Zielinska A, Choi J, Rho YH.

Rheumatology (Oxford). 2017 Oct 1;56(10):1771-1779. doi: 10.1093/rheumatology/kex254.

Supplemental Content

Loading ...
Support Center